Abstract
The senescent phenotype is repressed in rheumatoid arthritis and can be restored by the p16INK4a tumor suppressor gene (pages 760–767).
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Taniguchi T. et al. Induction of the p16INK4a senescence gene as a new therapeutic strategy for the treatment of rheumatoid arthritis. Nature Med. 5, 760–767 (1999).
Serrano, M., Hannon, G.J. & Beach, D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366, 704–707 (1993).
Nobori, T. et al. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368, 753– 756 (1994).
Sherr, C.J. Tumor surveillance via the ARF-p53 pathway. Genes Dev. 12, 2984–2991 (1998).
Chin, L., Pomerantz, J. & DePinho, R.A. The INK4a/ARF tumor suppressor: One gene—two products—two pathways. Trends Biochem. Sci. 23, 291–296 (1998).
Stein, G.H., Drullinger, L.F., Sonlard, A. & Dulic, V. Differential roles for cyclin-dependent kinase inhibitors p21 and p16 in the mechanisms of senescence and differentiation in human fibroblasts. Mol. Cell. Biol. 19, 2109–2117 (1999).
Cameron, E.E. et al. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nature Genet. 21, 103–107 (1999).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Carson, D., Haneji, N. Fighting arthritis with a senescence gene. Nat Med 5, 731–732 (1999). https://doi.org/10.1038/10447
Issue Date:
DOI: https://doi.org/10.1038/10447
This article is cited by
-
MRI for the assessment and monitoring of RA—what can it tell us?
Nature Reviews Rheumatology (2011)